Engineering more efficacious antibody therapy for myeloma.
In this issue of Blood, Tai et al describe a novel monoclonal antibody (mAb) for myeloma, which is both glycoengineered and conjugated to a cytotoxic agent. This mAb targets B-cell maturation antigen (BCMA) and has considerable preclinical activity, thus holding therapeutic promise. The outlook for myeloma patients has greatly improved over the past decade with the introduction of a number of novel agents. However, there is still a significant unmet need because many patients with gene expression profiling–defined good-risk disease eventually relapse and high-risk myeloma has poor long-term disease-free survival in the majority of patients.
UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES.
Frits
F
van Rhee
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D053301:B-Cell Maturation Antigen / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D053301:B-Cell Maturation Antigen; D000922:Immunotoxins